Study to Evaluate the Effects of Itraconazole and Rifampin on the Pharmacokinetics of ASC40 in Healthy Subjects

• Status: Completed
• Trial end date: 2021-05-14
• Target enrollment: 0
• Participant gender: All

Summary

The primary objective of this study is to evaluate the effects of itraconazole (a strong inhibitor of cytochrome P450 3A (CYP3A)) and rifampicin (a strong inducer of CYP3A) on the pharmacokinetics of ASC40 in healthy volunteers.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Ascletis Pharmaceuticals Co., Ltd.
• Treatments: Itraconazole; Rifampin

Criteria

Key Inclusion Criteria:

-19kg/m2 ≤ BMI <40kg/m2.

Key Exclusion Criteria:

• History of, or current digestive system, nervous system disease, etc..

• Taking drugs or foods that inhibit or induce the liver's metabolism.